Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer.

Hironori FujiiYunami YamadaDaichi WatanabeNobuhisa MatsuhashiTakao TakahashiKazuhiro YoshidaAkio Suzuki

Published in: Cancer chemotherapy and pharmacology (2018)

The present study demonstrated that dose reduction by 20% ensured safety and efficacy of irinotecan in mCRC patients with homozygous mutation in UGT1A1 genes.

Keyphrases

genome wide
gene expression
transcription factor
bioinformatics analysis